| Tumor stage | Non metastatic tumor n = 108 (84.5%) | Metastatic tumor at presentation n = 20 (15.5%) | Total (n = 128) (%) |
Age in years | less than 40 | 34 (31.5) | 8 (40.0) | 42 (32.8) |
40 to 60 | 63 (58.3) | 12 (60.0) | 75 (58.6) | |
More than 60 | 11 (10.2) | 0 | 11 (8.6) | |
Menopausal s | Premenopausal | 73 (67.6) | 18 (90.0) | 91 (71.1) |
Postmenopausal | 35 (32.4) | 2 (10.0) | 37 (28.9) | |
BMI | Less than 25 | 8 (7.4) | 2 (10.0) | 10 (7.8) |
25 to <30 | 57 (52.8) | 10 (50.0) | 67 (52.3) | |
30 or more | 43 (39.8) | 8 (40.0) | 51 (39.8) | |
Tumor size | T1 | 10 (9.3) | 0 | 10 (7.8) |
T2 | 54 (50.0) | 5 (25.0) | 59 (46.1) | |
T3 | 35 (32.4) | 6 (30.0) | 41 (32.0) | |
T4 | 9 (8.3) | 9 (45.0) | 18 (14.1) | |
Lymph node | N0 | 20 (18.5) | 0 | 23 (18.1) |
N1 | 55 (50.9) | 14 (73.7) | 67 (52.8) | |
N2 | 30 (27.8) | 5 (26.3) | 34 (26.7) | |
N3 | 3 (2.8) | 1 (5.0) | 4 (3.1) | |
Stage | I | 7 (5.5%) | IV = 20 (15.5%) |
|
II | 44 (34.4%) |
| ||
II | 57 (44.6%) |
| ||
LVI | Yes | 104 (69.3) | 20 (100) | 124 (96.9) |
No | 4 (3.7) | 0 | 4 (3.1) | |
K1 67 | Not done | 21 (19.4) | 4 (20.0) | 25 (19.5) |
less than 20 | 44 (50.6) | 2 (12.5) | 46 (35.9) | |
More than 20 | 43 (49.4) | 14 (87.5) | 57 (44.6) | |
Tumor grade | I | 1 (0.9) | 0 | 1 (0.8) |
II | 41 (38.0) | 7 (35.0) | 48 (37.5) | |
III | 66 (61.1) | 13 (65.0) | 79 (61.7) | |
Histopathology | IDC | 94 (87.1) | 13 (65.0) | 107 (83.6) |
ILC | 8 (7.4) | 1 (5.0) | 9 (7.0) | |
Others | 6 (5.5) | 6 (30.0) | 12 (9.4) | |
Surgery | MRM | 71 (65.7) | 0 |
|
BCS | 37 (34.3) | 0 |
| |
ALND | 100 (92.6) | 0 |
| |
SLN | 8 (7.4) | 0 |
| |
Neo adjuvant chemotherapy 34/108 (31.5%) | CR | 6 (17.6%) |
|
|
PR | 24 (70.6%) |
|
| |
No response | 4 (11.8%) |
|
| |
Types of chemotherapy | FAC | 14 (12.9%) |
| 14 (11%) |
AC and Taxol | 94 (87%) | 20 (100%) | 114 (89%) | |
Platinum/Gem | 0 (0%) | 20 (100%) | 20 (15.6%) | |
Taxotere | 0 (0%) | 12 (60%) |
| |
Xeloda | 0 (0%) | 6 (30%) |
| |
Adjuvant XRT | NO | 10 (9.3%) | 20 (100%) | 30 (23.4%) |
conventional | 56 (51.8%) | 0 | 56 (43.8%) | |
hypofractionation | 42 (38.9%) | 0 | 42 (32.8%) |